OLYMPIA Launch Phase Results Show Positive Outcomes in Diabetic Patients
NATICK, Mass. and VIENNA, Austria, Sept. 2 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced one-year results from the European and Intercontinental launch phases of its TAXUS OLYMPIA registry. The first 7,124 patient cohort of the nearly 23,000 enrolled provided positive safety data on the TAXUS(R) Liberate(TM) coronary stent system in complex, real-world patients, as announced at the European Society of Cardiology Congress in Vienna, Austria.
The one-year results demonstrated a low overall 3.9 percent rate of TAXUS Liberte stent related cardiac events, including cardiac death (1.1 percent), myocardial infarction (0.9 percent), and TAXUS Liberte stent related re-intervention of the target vessel (2.5 percent). The one-year stent thrombosis rate was 0.8 percent, which is consistent with safety data from other DES registries.
In the diabetic subset (2,380 patients), OLYMPIA reported a low 4.4 percent rate of overall TAXUS Liberte stent related cardiac events, including cardiac death (1.9 percent), and myocardial infarction (0.8 percent). TAXUS Liberte stent related re-interventions (2.3 percent) and stent thrombosis (0.7 percent) were both lower for the high-risk diabetic patient group than the rates for the overall population.
"The OLYMPIA registry continues to show impressive results, especially
given the high degree of complex patient and lesions from real-world
practice," said Martyn Thomas, M.D., F.R.C.P., Director of Invasive
Cardiology, Kings College Hospital, London, and one of the coordinating
investigators of the registry. "The data show consistency with initial
results and with dat
|SOURCE Boston Scientific Corporation|
Copyright©2007 PR Newswire.
All rights reserved